FDA concerns about the device Sanofi proposed to deliver two anti-diabetic agents will prolong the review of the combination product, and the delay likely will cause the company to forfeit the advantage gained from the expensive priority review voucher that it used to even the race to market with Novo Nordisk AS.
Sanofi announced Aug. 19 that FDA had requested more information on the pen delivery device that it has proposed for...







